Dr Laboni Sarkar (MD, DM Medical Oncology)

we are all in the gutter, but some of us are looking at the stars • MD medicine @ aiims, delhi • DM medical oncology @ tata memorial hospital, mumbai.

[Vincent Rajkumar @VincentRK]

Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI

Implications are HUGE. This is a drug we spends billions on each year:

-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD

National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG

https://t.co/k8nGWeSA03

[Vivek Subbiah, MD @VivekSubbiah]

🚨While @SpaceX goes IPO and the world's glued to @FIFAWorldCup ⚽🚀an interesting paper popped up for your Friday read @NatureMedicine
👉Frontier general LLMs (GPT-5.2, Gemini 3.1 Pro, Claude Opus 4.6) outperformed specialized clinical AI tools (OpenEvidence, UpToDate Expert AI) on medical knowledge, clinician alignment + 1,800 blinded physician annotations on real clinical queries🤯
👉This result was unexpected 🤯🤔 👉"Specialized" ≠ "Better" @OncoAlert
https://t.co/B0RmOhIZI2

[Jenna Taglienti @jenna_taglienti]

I wrote this in a moment I never would have chosen. A sudden pause that made me see my life clearly.

The meaning of our work is profound. This experience simply helped me see more clearly what matters most.

“Time is Finite” JAMA

https://t.co/IwkKdyeEWx

[Andrew Curran @AndrewCurran_]

Striking image from the new Anthropic labor market impact report.

[nicole ruiz @nwilliams030]

my favorite type of parent is the ones who are like

“screen time?

yeah unlimited screen time …

on our own server + the Linux machine, and they can just access anki, PowerPoint, and anything else they can figure out how to access by the CLI.”

[derek guy @dieworkwear]

When people think of menswear crafted with a high-degree of workmanship, they think of places such as France, Italy, and the UK. Some may think of Japan. But few will think of India, even though some of the most incredible workmanship is happening there now. Let me show you. 🧵

[Pramesh CS @cspramesh]

Issued in public interest

[Joseph Fasano @Joseph_Fasano_]

I first wrote this on the back of a student's paper, and two weeks later he turned in a paper about an issue he really cared about. It earned an A.

[ACS Journal Cancer @JournalCancer]

New & available #OpenAccess | Ten-year follow-up of outcomes, patterns of care, and psychosocial burden in adolescent and young adult (AYA) patients w/ bone sarcomas from a large cohort in a low-income and middle-income country (LMIC)

https://t.co/7hchBNOoh8

@oncoalert #ayacsm

[Luis Moreno Sánchez @radioncoluis]

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.

https://t.co/VY4H4BNciN

[Muthu Vaduganathan @mvaduganathan]

🚨#FLOW: The most anticipated trial of the year now published in @NEJM with #ERA24

Semaglutide 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself as a new pillar of care.

🧵 on key thoughts 👇🏾

https://t.co/5fbSxPSAMM

[President of India @rashtrapatibhvn]

President Droupadi Murmu launched India’s first home-grown gene therapy for cancer at IIT Bombay. The President said that as CAR-T cell therapy is accessible and affordable it provides a new hope for the whole of humankind. This is a praiseworthy example of academia-industry partnership, which should inspire many more similar efforts.
https://t.co/LFTMojBcxF

[President of India @rashtrapatibhvn]

India’s first CAR-T cell therapy is developed through collaboration between the Indian Institute of Technology, Bombay and Tata Memorial Hospital in association with industry partner ImmunoACT. So, we have two of India’s pioneering research institutes in their respective fields, joining hands with industry for a humanitarian cause.

[Dr Laboni Sarkar (MD, DM Medical Oncology) @drlaboni]

fascinating times ahead - with routine problems taken care of, we’ll hopefully be able to devote more time to areas requiring creativity and innovation. the bar is probably going to get a lot higher for all jobs, so honing your skill sets and identifying your niche will be key

[Cognition @cognition]

Today we're excited to introduce Devin, the first AI software engineer.

Devin is the new state-of-the-art on the SWE-Bench coding benchmark, has successfully passed practical engineering interviews from leading AI companies, and has even completed real jobs on Upwork.

Devin is an autonomous agent that solves engineering tasks through the use of its own shell, code editor, and web browser.

When evaluated on the SWE-Bench benchmark, which asks an AI to resolve GitHub issues found in real-world open-source projects, Devin correctly resolves 13.86% of the issues unassisted, far exceeding the previous state-of-the-art model performance of 1.96% unassisted and 4.80% assisted.

Check out what Devin can do in the thread below.

[Dr Laboni Sarkar (MD, DM Medical Oncology) @drlaboni]

@airvistara @netshrink still didn't answer the question that was asked. what precisely is the correlation between serving customers on time and non-vegetarian food?

[Pramesh CS @cspramesh]

A thread that demonstrates how life threatening social media can be...
Please don't follow random "influencers" who don't have true science to back them beyond "Trust me, bro"

[CrozrX @CrozrX]

Clinical characteristics, outcomes and prognostic factors in KRAS mutant 🫁 cancers: experience from a tertiary care cancer center in India 🇮🇳
@PatelOncology
🔻
https://t.co/TeV3PzMcpt

[Paolo Tarantino @PTarantinoMD]

Important update of the ABC trials. With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors. No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34). https://t.co/IBeps2yjhM

[Medivis @medivis_ai]

We are proud and thrilled to introduce SurgicalAR Vision on the Apple Store—a leap forward in surgical precision and patient care. Our mission to democratize medical imaging is further enhanced with this ability to integrate with Apple’s Vision Pro.

See the highest fidelity experience with SurgicalAR Vision today. Day 1 mindset.

https://t.co/3tUvxB0L4I

#AugmentedReality #AppleVisionPro #SpatialComputing #medicalimaging

[Paolo Tarantino @PTarantinoMD]

The highly debated results of PALOMA2 now published on JCO: the addition of palbociclib to 1L letrozole did not improve OS in HR+ MBC. The reason for the discrepancy with ribo & abema data remains unclear. Ultimately led to a reduction in the use of palbo.
https://t.co/shUjls4ar3